Kelyniam Global, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLYG research report →
Price Chart
About the company
Kelyniam Global, Inc. operates as a medical device manufacturer, providing specialized solutions for patients. The company creates custom prosthetics using computer-aided design (CAD) and manufacturing (CAM) processes, employing advanced medical-grade polymers.
- CEO
- Ross Bjella
- IPO
- 2008
- Employees
- 9
- HQ
- Canton, CT, US
Get TickerSpark's AI analysis on KLYG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.89M
- P/E
- -34.88
- PEG
- 0.02
- P/S
- 0.53
- P/B
- 11.06
- EV/EBITDA
- 14.33
- Div Yield
- 0.00%
- Gross Margin
- 77.32%
- Op Margin
- 3.35%
- Net Margin
- -6.00%
- ROE
- -29.31%
- ROIC
- 8.32%
Latest fiscal year · YoY change
- Revenue
- $3.05M-8.3%
- Gross Profit
- $2.30M+40.7%
- Op Income
- $-107,913
- Net Income
- $-138,555+84.9%
- EPS
- $-0.00+84.9%
- OCF Growth
- -287.2%
- FCF Growth
- -299.8%
- 52W High
- $0.30
- 52W Low
- $0.07
- 50D MA
- $0.14
- 200D MA
- $0.13
- Beta
- -0.10
- RSI (14)
- 59
- Avg Volume
- 6.06K
No earnings-call transcripts are available for KLYG yet.
- Free Float
- 21.7%
- Shares Outstanding
- 12.60M
- Float Shares
- 2.73M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 08 | Ketner James | other | 35,000 |
| Jun 25, 08 | Ketner James | other | 500,000 |
| Apr 7, 08 | Ketner James | buy | 4,800 |
| Apr 7, 08 | Ketner James | buy | 4,800 |
| Apr 3, 08 | Ketner James | other | 200,000 |
| Apr 3, 08 | Ketner James | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KLYG coverage
Recent articles, reports, and earnings notes.
No research on KLYG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KLYG report →Kelyniam Global Announces Q2 2026 Financial Results
accessnewswire.com · Aug 11
Kelyniam Global to Present at Planet MicroCap Las Vegas 2026 - From Single Product to Regenerative Medicine Leader
gurufocus.com · Jun 1
Kelyniam Global to Present at Planet MicroCap Las Vegas 2026 - From Single Product to Regenerative Medicine Leader
prnewswire.com · Jun 1
Kelyniam Global Announces Strong Q1 2026 Financial Results
prnewswire.com · May 11
Kelyniam Global Reports 2025 Financial Results
prnewswire.com · Mar 16
Kelyniam Global Announces Q3 2025 Financial Results
prnewswire.com · Nov 10
Kelyniam Global Renews Licensing Agreement with Finceramica, Unlocking Access to Valuable Pipeline Products
globenewswire.com · Nov 6
Kelyniam Global, Inc. Receives FDA Clearance for Innovative Fusion™ BCP-PEEK Implant
prnewswire.com · Sep 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.